307 related articles for article (PubMed ID: 30227879)
1. Efficient and tumor-specific knockdown of MTDH gene attenuates paclitaxel resistance of breast cancer cells both in vivo and in vitro.
Yang L; Tian Y; Leong WS; Song H; Yang W; Wang M; Wang X; Kong J; Shan B; Song Z
Breast Cancer Res; 2018 Sep; 20(1):113. PubMed ID: 30227879
[TBL] [Abstract][Full Text] [Related]
2. Reconstituted high density lipoprotein mediated targeted co-delivery of HZ08 and paclitaxel enhances the efficacy of paclitaxel in multidrug-resistant MCF-7 breast cancer cells.
Zhang F; Wang X; Xu X; Li M; Zhou J; Wang W
Eur J Pharm Sci; 2016 Sep; 92():11-21. PubMed ID: 27343697
[TBL] [Abstract][Full Text] [Related]
3. MTDH mediates trastuzumab resistance in HER2 positive breast cancer by decreasing PTEN expression through an NFκB-dependent pathway.
Du C; Yi X; Liu W; Han T; Liu Z; Ding Z; Zheng Z; Piao Y; Yuan J; Han Y; Xie M; Xie X
BMC Cancer; 2014 Nov; 14():869. PubMed ID: 25417825
[TBL] [Abstract][Full Text] [Related]
4. ShRNA targeting Notch1 sensitizes breast cancer stem cell to paclitaxel.
Mao J; Song B; Shi Y; Wang B; Fan S; Yu X; Tang J; Li L
Int J Biochem Cell Biol; 2013 Jun; 45(6):1064-73. PubMed ID: 23500524
[TBL] [Abstract][Full Text] [Related]
5. LINC00160 mediated paclitaxel-And doxorubicin-resistance in breast cancer cells by regulating TFF3 via transcription factor C/EBPβ.
Wu H; Gu J; Zhou D; Cheng W; Wang Y; Wang Q; Wang X
J Cell Mol Med; 2020 Aug; 24(15):8589-8602. PubMed ID: 32652877
[TBL] [Abstract][Full Text] [Related]
6. Establishment and characterization of MTDH knockdown by artificial MicroRNA interference - functions as a potential tumor suppressor in breast cancer.
Wang S; Shu JZ; Cai Y; Bao Z; Liang QM
Asian Pac J Cancer Prev; 2012; 13(6):2813-8. PubMed ID: 22938464
[TBL] [Abstract][Full Text] [Related]
7. Establishment of paclitaxel-resistant breast cancer cell line and nude mice models, and underlying multidrug resistance mechanisms in vitro and in vivo.
Chen SY; Hu SS; Dong Q; Cai JX; Zhang WP; Sun JY; Wang TT; Xie J; He HR; Xing JF; Lu J; Dong YL
Asian Pac J Cancer Prev; 2013; 14(10):6135-40. PubMed ID: 24289639
[TBL] [Abstract][Full Text] [Related]
8. Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles.
Wu Y; Zhang Y; Zhang W; Sun C; Wu J; Tang J
Colloids Surf B Biointerfaces; 2016 Feb; 138():60-9. PubMed ID: 26655793
[TBL] [Abstract][Full Text] [Related]
9. MTDH mediates estrogen-independent growth and tamoxifen resistance by down-regulating PTEN in MCF-7 breast cancer cells.
Xu C; Kong X; Wang H; Zhang N; Kong X; Ding X; Li X; Yang Q
Cell Physiol Biochem; 2014; 33(5):1557-67. PubMed ID: 24854844
[TBL] [Abstract][Full Text] [Related]
10. Cluster of Differentiation 44 Targeted Hyaluronic Acid Based Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in Ovarian Cancer.
Yang X; Iyer AK; Singh A; Milane L; Choy E; Hornicek FJ; Amiji MM; Duan Z
Pharm Res; 2015 Jun; 32(6):2097-109. PubMed ID: 25515492
[TBL] [Abstract][Full Text] [Related]
11. Cosilencing of PKM-2 and MDR-1 Sensitizes Multidrug-Resistant Ovarian Cancer Cells to Paclitaxel in a Murine Model of Ovarian Cancer.
Talekar M; Ouyang Q; Goldberg MS; Amiji MM
Mol Cancer Ther; 2015 Jul; 14(7):1521-31. PubMed ID: 25964202
[TBL] [Abstract][Full Text] [Related]
12. Estrogen receptor α attenuates therapeutic efficacy of paclitaxel on breast xenograft tumors.
Chang J; Sui M; Fan W
Breast Cancer Res Treat; 2012 Aug; 134(3):969-80. PubMed ID: 22374518
[TBL] [Abstract][Full Text] [Related]
13. Knockdown of metadherin inhibits angiogenesis in breast cancer.
Liu Y; Kong X; Li X; Li B; Yang Q
Int J Oncol; 2015; 46(6):2459-66. PubMed ID: 25902416
[TBL] [Abstract][Full Text] [Related]
14. Long non-coding RNA FTH1P3 activates paclitaxel resistance in breast cancer through miR-206/ABCB1.
Wang R; Zhang T; Yang Z; Jiang C; Seng J
J Cell Mol Med; 2018 Sep; 22(9):4068-4075. PubMed ID: 29971911
[TBL] [Abstract][Full Text] [Related]
15. Synergistic inhibition of breast cancer by co-delivery of VEGF siRNA and paclitaxel via vapreotide-modified core-shell nanoparticles.
Feng Q; Yu MZ; Wang JC; Hou WJ; Gao LY; Ma XF; Pei XW; Niu YJ; Liu XY; Qiu C; Pang WH; Du LL; Zhang Q
Biomaterials; 2014 Jun; 35(18):5028-38. PubMed ID: 24680191
[TBL] [Abstract][Full Text] [Related]
16. Biocompatible AIEgen/p-glycoprotein siRNA@reduction-sensitive paclitaxel polymeric prodrug nanoparticles for overcoming chemotherapy resistance in ovarian cancer.
Wu J; Wang Q; Dong X; Xu M; Yang J; Yi X; Chen B; Dong X; Wang Y; Lou X; Xia F; Wang S; Dai J
Theranostics; 2021; 11(8):3710-3724. PubMed ID: 33664857
[TBL] [Abstract][Full Text] [Related]
17. cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance.
Villeneuve DJ; Hembruff SL; Veitch Z; Cecchetto M; Dew WA; Parissenti AM
Breast Cancer Res Treat; 2006 Mar; 96(1):17-39. PubMed ID: 16322897
[TBL] [Abstract][Full Text] [Related]
18. Folic acid-coupled nano-paclitaxel liposome reverses drug resistance in SKOV3/TAX ovarian cancer cells.
Tong L; Chen W; Wu J; Li H
Anticancer Drugs; 2014 Mar; 25(3):244-54. PubMed ID: 24275314
[TBL] [Abstract][Full Text] [Related]
19. Lobaplatin inhibits breast cancer progression, cell proliferation while it induces cell apoptosis by downregulating MTDH expression.
Tian W; Hao S; Gao B; Jiang Y; Zhang X; Zhang S; Guo L; Zhao J; Zhang G; Chen Y; Li Z; Luo D
Drug Des Devel Ther; 2018; 12():3563-3571. PubMed ID: 30464390
[TBL] [Abstract][Full Text] [Related]
20. AMPK inhibits MTDH expression via GSK3β and SIRT1 activation: potential role in triple negative breast cancer cell proliferation.
Gollavilli PN; Kanugula AK; Koyyada R; Karnewar S; Neeli PK; Kotamraju S
FEBS J; 2015 Oct; 282(20):3971-85. PubMed ID: 26236947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
